Journal article

The prevalence, odds and predictors of lifespan comorbid eating disorder among people with a primary diagnosis of bipolar disorders, and vice-versa: Systematic review and meta-analysis

Michele Fornaro, Federico Manuel Daray, Fernando Hunter, Annalisa Anastasia, Brendon Stubbs, Domenico De Berardis, Jae Il Shin, Muhammad Ishrat Husain, Elena Dragioti, Paolo Fusar-Poli, Marco Solmi, Michael Berk, Eduard Vieta, Andre Ferrer Carvalho

Journal of Affective Disorders | ELSEVIER | Published : 2021


BACKGROUND: There are scarce and discrepant data about the prevalence and correlates of co-occurring eating disorders (EDs) among people with a primary diagnosis of bipolar disorder (BD), and vice-versa, compelling a systematic review and meta-analysis on the matter. METHODS: MEDLINE/PsycINFO databases were systematically searched for original studies documenting BD⇌ED comorbidity across the lifespan, from inception up until April 20th, 2020. Random-effects meta-analysis and meta-regression analyses were conducted, accounting for multiple moderators. RESULTS: Thirty-six studies involved 15,084 primary BD patients. Eleven studies encompassed 15,146 people with primary EDs. Binge eating disord..

View full abstract

University of Melbourne Researchers


Awarded by Health Education England (HEE)

Awarded by National Institute for Health Research (NIHR)

Awarded by NHMRC Senior Principal Research Fellowship

Funding Acknowledgements

MF, FD, FH, AA, DDB, JIS, ED, MS, AFC have no conflict of interest to disclose in conjunction with the present rereport. BS is supported by a Clinical Lectureship (ICA-CL-2017-03-001) jointly funded by Health Education England (HEE) and the National Institute for Health Research (NIHR). BS is part-funded by the NIHR Biomedical Research Centre at South London and Maudsley NHS Foundation Trust. BS also holds active grants with the Medical Research Council and Guys and St Thomas Charity (GSTT). The views expressed are those of the author(s) and not necessarily those of the (partner organization), the NHS, the NIHR, the Department of Health and Social Care, the MRC, or GSTT. MIH is a PI for a trial sponsored by COMPASS Pathways Limited for which he receives salary support and has previously served as Member, Board of Trustees for the Pakistan Institute of Living and Learning. MIH reports grants from the Brain and Behavior Research Foundation, Physician's Services Incorporated Foundation, Stanley Medical Research Institute, and the University of Toronto. MB is supported by a NHMRC Senior Principal Research Fellowship (1156072). EV has received grants and served as consultant, advisor or CME speaker for the following entities: AB-Biotics, Abbott, Allergan, Angelini, AstraZeneca, Bristol-Myers Squibb, Dainippon Sumitomo Pharma, Farmindustria, Ferrer, Forest Research Institute, Galenica, Gedeon Richter, Glaxo-Smith-Kline, Janssen, Lundbeck, Otsuka, Pfizer, Roche, Sage, Sanofi-Aventis, Servier, Shire, Sunovion, Takeda, the Brain and Behaviour Foundation, the Generalitat de Catalunya (PERIS), the Spanish Ministry of Science, Innovation and Universities (CIBERSAM), EU Horizon 2020, and the Stanley Medical Research Institute. PFP has received honoraria or grant fees from Lundbeck, Angelini, Menarini, Boehringer Ingelheim outside the current work.